[1] Patients should rotate injection sites within the same anatomical region (e.g., different areas of the abdomen) or between regions (abdomen, thigh, upper arm) with each dose
BEFORE WE START Is Noom Right For You
Understanding the BMI requirements for GLP-1 prescriptions is the first step in determining whether insurance is a viable path for you
Im pro-startup
Medical science has made such tremendous progress that there is hardly a healthy human left. Aldous Huxley GLP-1 Agonists at a Glance First-Generation (Short-Acting) Exenatide Byetta Lixisenatide Adlyxin / Lyxumia Second-Generation (Long-Acting) Exenatide ER Bydureon (weekly, now discontinued in some markets) Liraglutide Victoza (diabetes), Saxenda (obesity) Dulaglutide Trulicity Semaglutide Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral) Dual Agonist (GIP + GLP-1) Tirzepatide Mounjaro (diabetes), Zepbound (obesity) Triple or Combination Agonists (In Development) Retatrutide Triple agonist (GLP-1 + GIP + glucagon) CagriSema Combination of cagrilintide + semaglutide (GLP-1 + amylin analog) Orforglipron Oral, non-peptide GLP-1 receptor agonist (Eli Lilly) Danuglipron Oral small-molecule GLP-1 agonist (Pfizer) Efinopegdutide GLP-1/glucagon dual agonist (Merck/Biocon) AMG133 GLP-1 + GIP receptor modulator (Amgen)
Introduction The habitual use of laxative containing anthraquinone glycosides is considered to be the main cause of melanosis coli (MC) (1, 2)
